Eli Lilly showcases PhIII weight loss data for type 2 diabetes patients taking tirzepatide
Eli Lilly said new data from a Phase III trial showed that tirzepatide helped patients who are overweight or obese and have type 2 diabetes …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
